Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg slightly lowers target price on Sabre Insurance

(Sharecast News) - Analysts at Berenberg slightly lowered their target price on Sabre Insurance from 202.0p to 200.0p on Thursday ahead of the group's H1 results later this month. Berenberg noted that since its annual general meeting on 22 May, Sabre's share price was up 22% against a flat Stoxx Insurance index.

Although Berenberg expects to see a continuation in 2025 of the soft top-line trend developments seen since Q324, it also said it was "increasingly optimistic" about Sabre's long-term potential due to improving market conditions and the roll-out of its new IT platform in late H2/early FY26.

"Consequently, we believe the company can materially outperform consensus expectations in FY 2026 and FY 2027," said the German bank, which reiterated its 'buy' rating on the stock.

"Sabre trades on 9.1x Bloomberg 2026E EPS estimates, which is a 20% discount to the company's historical five-year average, with a 2025 dividend yield of 7.4%."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.